Physician profile
Paul E Puntney
NPI 1437261500
$1,698.97
in general payments reported to CMS, 2019-2025
14 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $17.24 · 2021: $452 · 2022: $99.75 · 2023: $458 · 2024: $273 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $870.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $248.16 | 2023-2024 | Izervay |
| Rxsight INC | $232.91 | 2023-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Sight Sciences, INC. | $200.17 | 2021-2022 | |
| Alcon Vision LLC | $170.09 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $124.40 | 2025 | Xdemvy |
| Apellis Pharmaceuticals, INC. | $110.19 | 2023 | Syfovre |
| Biotissue Holdings INC. | $107.43 | 2023 | |
| Kala Pharmaceuticals, INC. | $103.03 | 2021 | |
| Ivantis, INC | $93.18 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $88.96 | 2019 | |
| Ocular Therapeutix, INC. | $86.72 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $68.90 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $47.59 | 2024-2025 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Puntney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.